X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (18) 18
infectious diseases (13) 13
humans (12) 12
female (10) 10
male (10) 10
immunology (9) 9
antiretroviral therapy (8) 8
inflammation (8) 8
middle aged (8) 8
article (7) 7
epidemiology (7) 7
raltegravir (7) 7
risk factors (7) 7
adult (6) 6
aged (6) 6
atrial fibrillation (6) 6
cardiac & cardiovascular systems (6) 6
microbiology (6) 6
protease inhibitors (6) 6
anti-hiv agents - therapeutic use (5) 5
atazanavir (5) 5
atrial fibrillation - epidemiology (5) 5
hiv infections - drug therapy (5) 5
hiv-infected patients (5) 5
human immunodeficiency virus--hiv (5) 5
incidence (5) 5
raltegravir potassium - therapeutic use (5) 5
abridged index medicus (4) 4
atazanavir sulfate - therapeutic use (4) 4
darunavir - therapeutic use (4) 4
human immunodeficiency virus (4) 4
immune activation (4) 4
mortality (4) 4
prospective studies (4) 4
virology (4) 4
age factors (3) 3
aged, 80 and over (3) 3
analysis (3) 3
and commentaries (3) 3
antiretroviral drugs (3) 3
antiviral agents (3) 3
association (3) 3
biomarkers (3) 3
biomarkers - blood (3) 3
cardiovascular-disease (3) 3
cohort studies (3) 3
dosage and administration (3) 3
heart failure (3) 3
hiv (3) 3
lamivudine (3) 3
microbial translocation (3) 3
osteoprotegerin (3) 3
prevalence (3) 3
proportional hazards models (3) 3
research (3) 3
risk assessment - methods (3) 3
united states - epidemiology (3) 3
abacavir-lamivudine (2) 2
age (2) 2
algorithms (2) 2
anti-hiv agents - adverse effects (2) 2
antiretroviral agents (2) 2
antiretroviral treatment (2) 2
antiviral drugs (2) 2
articles and commentaries (2) 2
atherosclerosis risk (2) 2
atrial fibrillation - blood (2) 2
body composition (2) 2
body mass index (2) 2
body-composition changes (2) 2
bone mineral density (2) 2
c-reactive protein (2) 2
cardiovascular disease (2) 2
care and treatment (2) 2
clinical trials (2) 2
darunavir (2) 2
diabetes mellitus - epidemiology (2) 2
disease transmission (2) 2
drug therapy (2) 2
emtricitabine (2) 2
emtricitabine - therapeutic use (2) 2
epidemics (2) 2
failure (2) 2
health aspects (2) 2
heart failure - epidemiology (2) 2
hiv infection (2) 2
hiv infections - immunology (2) 2
hiv infections - virology (2) 2
influenza (2) 2
integrase inhibitors (2) 2
lipodystrophy (2) 2
macrophages (2) 2
major (2) 2
major and brief reports (2) 2
major articles (2) 2
major articles and brief reports (2) 2
management (2) 2
myocardial infarction - epidemiology (2) 2
original research (2) 2
outbreaks (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Statistical Methods in Medical Research, ISSN 0962-2802, 7/2018, Volume 27, Issue 7, pp. 2050 - 2059
Large outbreaks, such as those caused by influenza, put a strain on resources necessary for their control. In particular, children have been shown to play a... 
influenza | Reproductive number | H1N1 | transmission models | heterogeneity | social mixing | Intervention | Epidemics | Heterogeneity | Surveillance | Influenza | Outbreaks | Adults | Children | Closures | Age | Age differences | reproductive number
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 08/2019
Abstract In a retrospective case control analysis, following adjustments for high-sensitivity C-reactive protein (hsCRP), traditional cardiovascular risk... 
Journal Article
CLINICAL INFECTIOUS DISEASES, ISSN 1058-4838, 08/2019, Volume 69, Issue 4, pp. 676 - 686
Background. Despite effective antiretroviral therapy (ART), human immunodeficiency virus (HIV) infection remains associated with higher morbidity and... 
MORTALITY | INFECTIOUS DISEASES | MYOCARDIAL-INFARCTION | MARKER | ACUTE HIV-INFECTION | beta-D-glucan | MICROBIOLOGY | IMMUNOLOGY | COAGULATION BIOMARKERS | suPAR | INFLAMMATION | non-AIDS mortality | viral suppression | IMMUNE ACTIVATION | DYSFUNCTION | lipopolysaccharide binding protein | ASSOCIATION | and Commentaries
Journal Article
AIDS, ISSN 0269-9370, 04/2019
Before initiation of antiretroviral therapy (ART), levels of sST2 were not elevated in people living with HIV who later developed non-AIDS events (including... 
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 05/2018, Volume 66, Issue 11, pp. 1794 - 1797
In this randomized pilot clinical trial, dolutegravir plus lamivudine was noninferior to continuation of standard 3-drug maintenance antiretroviral therapy.... 
2-drug | maintenance therapy | Dolutegravir | lamivudine | Brief Reports
Journal Article
AIDS, ISSN 0269-9370, 07/2019, Volume 33, Issue 8, pp. 1397 - 1399
Before initiation of antiretroviral therapy (ART), levels of soluble suppression of tumorigenicity 2 (sST2) were not elevated in people living with HIV who... 
ST2 | INFECTIOUS DISEASES | VIROLOGY | IMMUNOLOGY | Antiviral agents | HIV patients | Usage | Research | Health aspects | Heart attack
Journal Article
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 08/2019
A retrospective case control analysis determined that following adjustment for hsCRP, presence of traditional cardiovascular risk factors and CD4/CD8 T cell... 
Journal Article
Journal of Infectious Diseases, ISSN 0022-1899, 10/2015, Volume 212, Issue 8, pp. 1241 - 1249
Background. Specific antiretroviral therapy (ART) medications and the severity of human immunodeficiency virus (HIV) disease before treatment contribute to... 
human immunodeficiency virus | bone mineral density | protease inhibitor | inflammation | integrase inhibitor | INTIMA-MEDIA THICKNESS | INFECTIOUS DISEASES | ABACAVIR-LAMIVUDINE | TURNOVER | EMTRICITABINE | MICROBIOLOGY | OSTEOPROTEGERIN | IMMUNOLOGY | HIV-INFECTED ADULTS | PROTEASE INHIBITORS | THERAPY | RECEPTOR ACTIVATOR | Raltegravir Potassium - adverse effects | Humans | Middle Aged | Raltegravir Potassium - therapeutic use | Male | Atazanavir Sulfate - adverse effects | HIV - drug effects | Viral Load | Reverse Transcriptase Inhibitors - adverse effects | Young Adult | Ritonavir - adverse effects | Ritonavir - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | Reverse Transcriptase Inhibitors - therapeutic use | Drug Therapy, Combination | HIV Protease Inhibitors - adverse effects | Emtricitabine - adverse effects | Emtricitabine - therapeutic use | Tenofovir - adverse effects | Tenofovir - therapeutic use | Anti-HIV Agents - adverse effects | HIV Protease Inhibitors - therapeutic use | Atazanavir Sulfate - therapeutic use | Bone Density - drug effects | HIV Integrase Inhibitors - adverse effects | HIV Integrase Inhibitors - therapeutic use | HIV Infections - drug therapy | Darunavir - adverse effects | HIV Infections - physiopathology | Darunavir - therapeutic use | Antiviral agents | Care and treatment | Analysis | Bones | Dosage and administration | Inflammation | HIV infection | Density | Risk factors | Major and Brief Reports
Journal Article
Journal Article
JAIDS Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 07/2018, Volume 78, Issue 3, pp. 362 - 366
BACKGROUND:The contributions of the receptor activator of nuclear factor kappa-B ligand (RANKL)/osteoprotegerin (OPG) axis to cardiovascular and bone disease... 
Journal Article
JAIDS Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 07/2018, Volume 78, Issue 3, pp. 362 - 366
Journal Article
Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 07/2018, Volume 78, Issue 3, p. 362
Background: The contributions of the receptor activator of nuclear factor kappa-B ligand (RANKL)/osteoprotegerin (OPG) axis to cardiovascular and bone disease... 
Plasma | Therapy | Spine | Ritonavir | Clinical trials | Infections | Osteoprotegerin | Tenofovir | Randomization | Antiretroviral agents | Human immunodeficiency virus--HIV | Biocompatibility | Carotid artery | TRANCE protein | Emtricitabine | Ribonucleic acid--RNA | Patients | Morbidity | Antiretroviral therapy | Hip | Correlation analysis | Ligands | Bone mineral density | Plasma levels | Antiviral drugs
Journal Article
Journal of the American Heart Association, ISSN 2047-9980, 2013, Volume 2, Issue 2, p. e000102
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 06/2018, Volume 66, Issue 11, p. 1794
In this randomized pilot clinical trial, dolutegravir plus lamivudine was noninferior to continuation of standard 3-drug maintenance antiretroviral therapy.... 
Antiretroviral drugs | Randomization | Protease inhibitors | Antiretroviral agents | Human immunodeficiency virus--HIV | Viruses | Lamivudine | Drug resistance | Antiretroviral therapy
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 04/2019, Volume 68, Issue 8, pp. 1394 - 1401
In a randomized antiretroviral therapy initiation trial, raltegravir, darunavir/ritonavir, and atazanavir/ritonavir demonstrated similar changes in gut... 
INFECTIOUS DISEASES | gut integrity | RALTEGRAVIR | INITIATION | MICROBIOLOGY | IMMUNOLOGY | HUMAN-IMMUNODEFICIENCY-VIRUS | microbial translocation | body composition | OBESITY | HIV | INSULIN-RESISTANCE | INFLAMMATION | PREDICT MORTALITY | IMMUNE ACTIVATION | INTESTINAL BARRIER | and Commentaries
Journal Article
The Journal of Clinical Endocrinology & Metabolism, ISSN 0021-972X, 04/2019, Volume 104, Issue 10, pp. 4857 - 4864
Context: Microscopic measurement of adipocyte size is the gold standard for determining adipose tissue (AT) quality. AT density on CT may also reflect... 
TENOFOVIR-EMTRICITABINE | ABACAVIR-LAMIVUDINE | SUBCUTANEOUS ADIPOSE-TISSUE | METABOLISM | ATAZANAVIR-RITONAVIR | EFAVIRENZ | ENDOCRINOLOGY & METABOLISM | CARDIOVASCULAR-DISEASE | WEIGHT-LOSS | HEALTH | ASSOCIATION
Journal Article